Biomarkers

Mutations in SERPINB3, SERPINB4 or IFNγ pathway genes could help predict responses to Yervoy ipilimumab in melanoma patients. In a cohort of 174 Yervoy-treated patients, tumor mutations in SERPINB3 or SERPINB4 were associated with therapeutic responses and survival. In a second cohort of 104 Yervoy-treated patients, mutations in 66 IFNγ pathway genes, including interferon γ receptor 1 (IFNGR1), IFNGR2 and Janus kinase-2 (JAK-2), were associated with poor therapeutic responses. Next steps could include validating the mutations in larger cohorts...